BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 19758638)

  • 21. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy.
    Chun FK; Briganti A; Lebeau T; Fradet V; Steuber T; Walz J; Schlomm T; Eichelberg C; Haese A; Erbersdobler A; McCormack M; Perrotte P; Graefen M; Huland H; Karakiewicz PI
    Eur Urol; 2006 Feb; 49(2):273-8; discussion 278-9. PubMed ID: 16413103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
    J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.
    Bauer JJ; Connelly RR; Seterhenn IA; Deausen J; Srivastava S; McLeod DG; Moul JW
    J Urol; 1998 Mar; 159(3):929-33. PubMed ID: 9474185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
    J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of surgical margin status for biochemical recurrence following radical prostatectomy.
    Hashimoto K; Masumori N; Takei F; Fukuta F; Takahashi A; Itoh N; Hasegawa T; Tsukamoto T
    Jpn J Clin Oncol; 2008 Jan; 38(1):31-5. PubMed ID: 18203710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy.
    Steuber T; Erbersdobler A; Graefen M; Haese A; Huland H; Karakiewicz PI
    Cancer; 2006 Feb; 106(4):775-82. PubMed ID: 16400637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer.
    Ramos CG; Roehl KA; Antenor JA; Humphrey PA; Catalona WJ
    J Urol; 2004 Jul; 172(1):137-40. PubMed ID: 15201754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3-year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: experience from a tertiary referral center in the United States.
    Pavlovich CP; Trock BJ; Sulman A; Wagner AA; Mettee LZ; Su LM
    J Urol; 2008 Mar; 179(3):917-21; discussion 921-2. PubMed ID: 18207191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low p27 expression predicts poor disease-free survival in patients with prostate cancer.
    Yang RM; Naitoh J; Murphy M; Wang HJ; Phillipson J; deKernion JB; Loda M; Reiter RE
    J Urol; 1998 Mar; 159(3):941-5. PubMed ID: 9474188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.
    Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Blute ML
    J Urol; 2008 Apr; 179(4):1354-60; discussion 1360-1. PubMed ID: 18289596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy.
    Pierorazio PM; Lambert SM; Matsukhani M; Sprenkle PC; McCann TR; Katz AE; Olsson CA; Benson MC; McKiernan JM
    BJU Int; 2007 Nov; 100(5):1066-70. PubMed ID: 17784880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
    Massengill JC; Sun L; Moul JW; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Donahue T
    J Urol; 2003 May; 169(5):1670-5. PubMed ID: 12686805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A close surgical margin after radical prostatectomy is an independent predictor of recurrence.
    Lu J; Wirth GJ; Wu S; Chen J; Dahl DM; Olumi AF; Young RH; McDougal WS; Wu CL
    J Urol; 2012 Jul; 188(1):91-7. PubMed ID: 22578729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
    BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.